Huadong Medicine's (SHE:000963) unit, Hangzhou Sino-American Huadong Pharmaceutical, received approval from the U.S. Food and Drug Administration for the clinical trial of injectable HDM2024, according to a Thursday disclosure on the Shenzhen bourse.
The Chinese drugmaker will conduct phase I clinical trials to test the drug as a treatment for advanced solid tumors in the U.S.
The company's shares slipped over 1% during the morning trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments